U.S. rests its case in insider trading trial of SAC's Martoma - News and Current Events | futures io social day trading
futures io futures trading


U.S. rests its case in insider trading trial of SAC's Martoma
Updated: Views / Replies:156 / 0
Created: by kbit Attachments:0

Welcome to futures io.

(If you already have an account, login at the top of the page)

futures io is the largest futures trading community on the planet, with over 90,000 members. At futures io, our goal has always been and always will be to create a friendly, positive, forward-thinking community where members can openly share and discuss everything the world of trading has to offer. The community is one of the friendliest you will find on any subject, with members going out of their way to help others. Some of the primary differences between futures io and other trading sites revolve around the standards of our community. Those standards include a code of conduct for our members, as well as extremely high standards that govern which partners we do business with, and which products or services we recommend to our members.

At futures io, our focus is on quality education. No hype, gimmicks, or secret sauce. The truth is: trading is hard. To succeed, you need to surround yourself with the right support system, educational content, and trading mentors – all of which you can find on futures io, utilizing our social trading environment.

With futures io, you can find honest trading reviews on brokers, trading rooms, indicator packages, trading strategies, and much more. Our trading review process is highly moderated to ensure that only genuine users are allowed, so you don’t need to worry about fake reviews.

We are fundamentally different than most other trading sites:
  • We are here to help. Just let us know what you need.
  • We work extremely hard to keep things positive in our community.
  • We do not tolerate rude behavior, trolling, or vendors advertising in posts.
  • We firmly believe in and encourage sharing. The holy grail is within you, we can help you find it.
  • We expect our members to participate and become a part of the community. Help yourself by helping others.

You'll need to register in order to view the content of the threads and start contributing to our community.  It's free and simple.

-- Big Mike, Site Administrator

Reply
 
Thread Tools Search this Thread
 

U.S. rests its case in insider trading trial of SAC's Martoma

  #1 (permalink)
Elite Member
Aurora, Il USA
 
Futures Experience: Advanced
Platform: TradeStation
Favorite Futures: futures
 
kbit's Avatar
 
Posts: 5,872 since Nov 2010
Thanks: 3,301 given, 3,332 received

U.S. rests its case in insider trading trial of SAC's Martoma

(Reuters) - Steven A. Cohen tried to sell stock as quietly as possible as SAC Capital Advisors unwound positions at the center of an insider trading trial, the hedge fund's head trader said on Thursday.

The testimony came as the government called its final witnesses in the trial of former portfolio manager Mathew Martoma, putting the case within days of its conclusion.

Martoma, 39, is accused of using inside information about a drug trial to trade in the stock of Elan Corp Plc and Wyeth that helped SAC Capital make profits and avoid losses of $276 million.

Much of that trading took place in accounts controlled by Cohen after prosecutors say Martoma received a tip about negative results for a clinical trial for an Alzheimer's drug being developed by Elan and Wyeth.

"Steve wanted to start selling Elan and he wanted to put in accounts that didn't have as much visibility" inside SAC Capital, Phillipp Villhauer, the hedge fund's top trader, testified.

That included making trades through accounts that only about 15 of SAC's roughly 900 employees could view, he said, and using computer algorithms and "dark pools" instead of public exchanges to make the trades.

Under questioning by a lawyer for Martoma, Villhauer said there was "absolutely nothing improper" about the methods SAC used to minimize transparency of the trades, saying big investors used the tactic to avoid causing a stock price to fall during a sale.

Cohen, 57, has not been charged with a crime, although the U.S. Securities and Exchange Commission is seeking to bar him from the financial industry for failing to supervise Martoma and another employee the agency says took part in insider trading.

Villhauer was among the final three witnesses in the government's case against Martoma, shifting the case to Martoma's defense team.

Lawyers for Martoma called their first two witnesses Tuesday afternoon, including Peter Nussbaum, the general counsel for SAC Capital, who testified to an arrangement the hedge fund had with a former SAC portfolio manager to give advice on Wyeth.

The former portfolio, Wayne Holman, had left SAC Capital in 2006 and started up his own hedge fund, Ridgeback Capital Management. SAC Capital entered into a deal with Holman to advise on investing in Wyeth in November 2007, Nussbaum said.

"He was expected to provide his advice on Wyeth to Steve," Nussbaum said.

The testimony could help bolster an argument by Martoma's lawyers that SAC's investments in Wyeth were not based solely on any of the information focused on by prosecutors.

Cohen has said in a deposition with the SEC that he decided to sell SAC Capital's position in Wyeth after speaking with Holman. Martoma's lawyers had sought to introduce the deposition at trial, but U.S. Judge Paul Gardephe denied the bid.

TWO DOCTORS

Over 12 days during the trial, prosecutors called 20 witnesses as they sought a conviction of an eighth current or former employee of Cohen's hedge fund.

SAC Capital agreed last year to pay $1.8 billion in criminal and civil settlements and plead guilty to fraud charges stemming from insider trading by its employees.

Among the government witnesses was Sidney Gilman, a doctor who chaired the safety monitoring committee for the drug trial and testified to regularly speaking with Martoma through paid consultations arranged through Gerson Lehrman Group, a firm that connects experts with investors.

But Gilman's memory was repeatedly tested while on the stand. The 81-year-old former University of Michigan professor said he had "some holes in my memory" regarding a key meeting with Martoma in July 2008 ahead of the negative results being announced.

Other government witnesses included Joel Ross, a New Jersey doctor who acted as a clinical investor on the trial for the Alzheimer's drug, bapineuzumab, and said he also provided confidential information to Martoma. Both he and Gilman are testifying pursuant to non-prosecution agreements.

Richard Strassberg, Martoma's lawyer, said he expected to finish the case for the defense by Thursday. Closing arguments could come as early as Friday, Gardephe said.

U.S. rests its case in insider trading trial of SAC's Martoma | Reuters

Reply With Quote

Reply



futures io > > > > U.S. rests its case in insider trading trial of SAC's Martoma

Thread Tools Search this Thread
Search this Thread:

Advanced Search



Upcoming Webinars and Events (4:30PM ET unless noted)

Linda Bradford Raschke: Reading The Tape

Elite only

Adam Grimes: TBA

Elite only

NinjaTrader: TBA

January

Ran Aroussi: TBA

Elite only
     

Similar Threads
Thread Thread Starter Forum Replies Last Post
SAC Manager Insider Case May Be Tough to Prove Quick Summary News and Current Events 0 April 1st, 2013 08:10 AM
7 charged in $62 million Dell insider-trading case kbit News and Current Events 0 January 18th, 2012 04:14 PM
Tipster sentenced in NYC insider trading case kbit News and Current Events 2 December 1st, 2011 10:58 PM
SEC Dismisses Insider Trading Case Against Rajat Gupta kbit News and Current Events 0 August 4th, 2011 07:07 PM
Gupta's Insider-Trading Case Could Be Bigger Than Madoff Quick Summary News and Current Events 0 March 1st, 2011 07:20 PM


All times are GMT -4. The time now is 01:29 PM.

Copyright © 2017 by futures io, s.a., Av Ricardo J. Alfaro, Century Tower, Panama, +507 833-9432, info@futures.io
All information is for educational use only and is not investment advice.
There is a substantial risk of loss in trading commodity futures, stocks, options and foreign exchange products. Past performance is not indicative of future results.
no new posts
Page generated 2017-12-11 in 0.07 seconds with 19 queries on phoenix via your IP 54.145.16.43